Drug Interaction Report
1 potential interaction and/or warning found for the following 2 drugs:
- pasireotide
- Vimpat (lacosamide)
Interactions between your drugs
lacosamide pasireotide
Applies to: Vimpat (lacosamide), pasireotide
MONITOR: The risk of significant bradycardia and atrioventricular (AV) block may be increased during concomitant treatment of pasireotide with other drugs that slow heart rate or AV conduction such as beta-blockers, calcium channel blockers, atazanavir, digitalis, flecainide, lacosamide, mefloquine, moricizine, and propafenone.
MANAGEMENT: Pasireotide has not been studied in patients receiving other bradycardic drugs. Because bradycardia and AV block are recognized risk factors for torsade de pointes arrhythmia, electrocardiographic monitoring is recommended prior to initiation of pasireotide and during treatment. Dose adjustments of beta blockers and calcium channel blockers or correction of electrolyte disturbances may be necessary.
References (5)
- (2001) "Product Information. Exelon (rivastigmine)." Novartis Pharmaceuticals
- Cerner Multum, Inc. "UK Summary of Product Characteristics."
- Canadian Pharmacists Association (2006) e-CPS. http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink
- Cerner Multum, Inc. "Australian Product Information."
- (2013) "Product Information. Signifor (pasireotide)." Novartis Pharmaceuticals
Drug and food interactions
No alcohol/food interactions were found with the drugs in your list. However, this does not necessarily mean no food interactions exist. Always consult your healthcare provider.
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Report options
- Switch to consumer interaction data
- Email this report to a friend, doctor, or patient
- Ask questions, find answers
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
See also:
Sandostatin
Sandostatin is used to treat acromegaly and to reduce flushing episodes and watery diarrhea caused ...
Sandostatin LAR Depot
Sandostatin LAR Depot is used for acromegaly, carcinoid tumor, vasoactive intestinal peptide tumor
Ozempic
Learn about Ozempic (semaglutide) for type 2 diabetes treatment, weight management, cardiovascular ...
Somatuline Depot
Somatuline Depot is used as a long-term treatment for acromegaly. Learn about side effects ...
Parlodel
Parlodel is used for acromegaly, hyperprolactinemia, parkinson's disease
Signifor
Signifor (pasireotide) is a man-made protein that is similar to somatostatin and is used to treat ...
Cycloset
Cycloset is used to treat Type 2 Diabetes. Learn about side effects, interactions and indications.
Mycapssa
Mycapssa (octreotide) is used for the treatment of acromegaly. Includes Mycapssa side effects ...
Bromocriptine
Bromocriptine is used for acromegaly, hyperprolactinemia, parkinson's disease, tardive dyskinesia ...
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.